Track PURE Bioscience's accounts payable ($720K) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
The latest accounts payable for PURE is $720K as of April 2026. That compares with $800K in the prior-year period — down 10.0% year over year. Investors often review this figure alongside PURE Bioscience's historical trend and sector peers before judging valuation or financial health.
Over the past year, PURE's accounts payable moved from $800K to $720K — a 10.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in PURE Bioscience's operating scale or balance-sheet position.
A accounts payable figure of $720K for PURE is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.
After noting PURE's accounts payable ($720K), review year-over-year change from $800K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.